NAD+ complete guide

NAD+ — nicotinamide adenine dinucleotide — is one of the most-studied small molecules in biochemistry. It is a pyridine-nucleotide coenzyme present in every living cell, the obligate electron carrier of catabolic metabolism, and the substrate for three enzyme classes that together place it at the centre of the modern cellular-aging research conversation: sirtuin deacetylases, poly(ADP-ribose) polymerases (PARPs), and CD38 NADases. Tissue NAD+ levels decline markedly with age in research-animal models, and the question of whether boosting NAD+ availability modulates age-related phenotypes is the engine driving most of the longevity-pharmacology literature of the last fifteen years.

This guide is a mechanism-focused deep-dive: where NAD+ comes from, how the three NAD+-consuming enzyme classes operate, why levels fall with age, what the published mitochondrial and longevity research actually documents, and how NAD+ sits relative to its precursors NMN and NR. Everything is research-frame language. No protocol guidance. No clinical recommendations.

Quick reference — NAD+ identifiers

Property	NAD+
Class	Pyridine-nucleotide coenzyme
Full name	Nicotinamide adenine dinucleotide (oxidized form)
Molecular formula	C21H27N7O14P2
Molecular weight	663.43 g/mol
CAS	53-84-9
PubChem CID	5893
Origin	Synthesized de novo from tryptophan via the kynurenine pathway, or recycled via NAD+ salvage from nicotinamide (NAMPT-dependent)
Plasma half-life	Short — NAD+ is compartmentalized intracellularly; circulating pool is small relative to tissue pool
Vial strengths (TogoPeptide)	100 mg lyophilized; smaller vial formats may exist depending on batch

Origin and structure — pyridine-nucleotide coenzyme

NAD+ is a dinucleotide composed of two nucleotides joined by a pair of phosphate groups: one nucleotide carries the nicotinamide (vitamin B3 derivative) base, the other carries adenine. The nicotinamide ring is the redox-active component — accepting and donating a hydride ion (H⁻) at the 4-position of the pyridine ring. This is the chemistry that defines NAD+ as a coenzyme.

Two redox states matter:

• NAD+ (oxidized) — the hydride acceptor, written as the cation form. This is the species consumed by sirtuins, PARPs and CD38.
• NADH (reduced) — the hydride-loaded form generated during glycolysis, the TCA cycle, and fatty-acid oxidation. NADH delivers electrons to Complex I of the mitochondrial electron transport chain.

A phosphorylated variant, NADP+/NADPH, runs a parallel but distinct pool dedicated mostly to reductive biosynthesis (fatty-acid synthesis, cholesterol synthesis) and antioxidant defence (glutathione recycling). The NAD+/NADH ratio is the catabolic ratio; NADP+/NADPH is the anabolic ratio.

Three biosynthesis routes feed the cellular NAD+ pool:

• De novo synthesis from tryptophan — the kynurenine pathway converts dietary tryptophan to quinolinic acid and then to NAD+ over eight enzymatic steps. Quantitatively a minor contributor in most tissues, but the only fully-independent route.
• NAD+ salvage from nicotinamide — the dominant route in most cells. NAMPT (nicotinamide phosphoribosyltransferase) converts nicotinamide back into NMN, which NMNAT enzymes then adenylate to regenerate NAD+. This pathway recycles the nicotinamide released every time a sirtuin, PARP or CD38 consumes an NAD+ molecule.
• Precursor entry — NMN and NR — nicotinamide mononucleotide (NMN) enters the salvage pathway one step downstream of NAMPT; nicotinamide riboside (NR) enters via NRK kinases. Both are the basis of the precursor-supplementation research line.

Mechanism — three enzyme classes consume NAD+

Unlike most coenzymes, NAD+ is not only used catalytically. Three enzyme classes consume NAD+ as a stoichiometric substrate — cleaving the molecule and releasing nicotinamide as a byproduct. This consumption is what links NAD+ availability to cellular phenotypes that have nothing directly to do with redox metabolism.

Sirtuin deacetylase activity

The sirtuin family (SIRT1 through SIRT7 in mammals) are NAD+-dependent lysine deacetylases. They remove acetyl groups from lysine residues on histones and on a wide set of non-histone substrate proteins, coupling each deacetylation event to the cleavage of one molecule of NAD+ [1]. Their substrates include the transcription factors FOXO3a, p53, NF-κB, and the mitochondrial-biogenesis coactivator PGC-1α.

Because the enzymatic activity is NAD+-dependent, sirtuins effectively read the cellular NAD+/NADH ratio as a metabolic signal. The Guarente and Sinclair laboratories established this NAD+/sirtuin axis as the mechanistic bridge between calorie-restriction phenotypes (which raise NAD+) and the gene-expression patterns characteristic of metabolic adaptation and stress resistance. SIRT1 (nuclear/cytosolic) and SIRT3 (mitochondrial) are the most-studied members of the family.

PARP DNA-repair activity

Poly(ADP-ribose) polymerases — PARP1 dominantly, with smaller contributions from PARP2 and other family members — consume NAD+ to build poly-ADP-ribose chains on target proteins at sites of DNA damage. PARP1 is one of the earliest responders to single- and double-strand DNA breaks. Each ADP-ribose unit added to a substrate consumes one NAD+ molecule, and a robust DNA-damage response can deplete cellular NAD+ pools rapidly [2].

Because DNA damage accumulates with age, PARP-mediated NAD+ consumption rises as a function of biological age — one of the documented mechanisms by which the NAD+ pool shrinks over the lifespan in research-animal models.

CD38 hydrolase activity

CD38 is a transmembrane NADase — it hydrolyses NAD+ to nicotinamide and ADP-ribose (or, at lower stoichiometry, to the calcium-mobilizing second messenger cyclic ADP-ribose). CD38 expression rises with age, particularly in immune cells of the spleen, liver and adipose tissue, and the work of the Verdin and Chini laboratories identified CD38 as the dominant driver of age-related NAD+ decline in research-mouse models [5]. CD38-knockout animals retain near-young NAD+ levels into late life, confirming the causal role of the enzyme.

CD38 upregulation is itself driven by chronic low-grade inflammation (sometimes called inflammaging), which connects the immune-aging line of research to the NAD+-decline line of research at a single mechanistic node.

Mitochondrial function research

The classical role of NAD+ is as the obligate electron carrier of catabolic metabolism. NADH generated in the cytosol (glycolysis) and the mitochondrial matrix (TCA cycle, fatty-acid β-oxidation) delivers electrons to Complex I of the electron transport chain, which uses the redox energy to pump protons across the inner mitochondrial membrane and ultimately drive ATP synthesis at Complex V. Without an adequate NAD+ pool, glycolytic and TCA flux stall.

Beyond the immediate redox role, NAD+ controls mitochondrial biogenesis through the SIRT1→PGC-1α axis. SIRT1 deacetylates and activates PGC-1α, the master transcriptional coactivator of mitochondrial biogenesis. Falling NAD+ silences SIRT1, leaves PGC-1α in its inactive acetylated state, and reduces the rate at which new mitochondria are produced. The Sinclair laboratory documented this as a pseudohypoxic state in aged tissue — reduced mitochondrial respiration despite adequate oxygen, traceable to the NAD+/SIRT1/HIF-1α signaling cascade [6].

Age-related NAD+ decline

Tissue NAD+ measurements in published research-animal models document substantial decline across the lifespan. In rodent skeletal muscle, liver, brain and adipose tissue, NAD+ levels fall by approximately 50–80% from young adulthood to senescence. The pattern has been replicated in human-tissue biopsy work for skin, skeletal muscle and brain, although the absolute magnitude varies by tissue and the methodology is harder in humans than in inbred-strain rodent designs.

The decline is mechanistically multifactorial — rising CD38 expression is the dominant driver, with PARP activation by accumulated DNA damage as a secondary contributor, and modest declines in NAMPT expression as a third. The relative weighting differs by tissue: liver is more PARP-driven, adipose and immune tissue more CD38-driven.

Longevity research line

The connection between NAD+ availability and longevity-relevant phenotypes runs through the sirtuin pathway. Calorie restriction — the longest-validated longevity intervention in research-animal models — raises tissue NAD+/NADH ratios and activates sirtuin signaling. The Sinclair laboratory and others have established that pharmacological sirtuin activators, NAD+-precursor supplementation, and CD38 inhibition all converge on similar gene-expression patterns and metabolic phenotypes in research-mouse designs [3].

The published longevity-research outcomes documented in research-animal models with NAD+-boosting interventions include improved mitochondrial function, restored insulin sensitivity, preserved skeletal-muscle performance, improved neurovascular function in aged brain tissue, and modest but reproducible lifespan extension in some genetic backgrounds. The translation to human research remains the open question, with several precursor compounds in active clinical investigation.

NAD+ vs NMN vs NR — precursor research

Three molecules feed the salvage pathway that ultimately produces cellular NAD+. They differ in entry point, bioavailability profile and the published research depth supporting each [4].

Aspect	NAD+ (direct)	NMN	NR
Full name	Nicotinamide adenine dinucleotide	Nicotinamide mononucleotide	Nicotinamide riboside
Molecular weight	663.43 g/mol	334.22 g/mol	255.25 g/mol
Salvage entry point	Already the end product	Downstream of NAMPT (one step from NAD+ via NMNAT)	Upstream of NAMPT (converted via NRK kinases to NMN)
Stability profile	Larger molecule, sensitive to light/heat	Intermediate stability	Most stable as solid; readily hydrolysed in solution
Research-line depth	Direct administration models, mitochondrial biochemistry	Sinclair-line longevity work, calorie-restriction overlap	Brenner-line ChromaDex-affiliated research, human pharmacokinetics

The choice between direct NAD+ and the precursor molecules in research designs is driven by what the experimental question demands — direct NAD+ for short-window biochemistry and mitochondrial-isolation work, precursors for longer-window salvage-pathway and lifespan designs.

Storage and handling

NAD+ ships as lyophilized powder, typically off-white to pale yellow. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window when kept cold and dry.
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent. Aqueous NAD+ solutions are pH-sensitive — strongly acidic or alkaline conditions accelerate hydrolysis.
• Reconstituted state: refrigerate at 2–8°C and protect from light. NAD+ is appreciably less stable in solution than as the lyophilized solid; use within a short window relative to other peptide compounds.
• Light and oxygen sensitivity: the nicotinamide ring is photo-active and oxidation-sensitive. Minimise light exposure and headspace air during handling.
• Avoid freeze-thaw cycles after reconstitution.

Each TogoPeptide NAD+ shipment includes a per-batch Certificate of Analysis with HPLC purity, mass-spectrometry identity confirmation, lot number, manufacture date, and analysis date. See how to read a COA or reconstitution methodology for the methodology details.

Cross-research lines and pairings

• Longevity Stack — cellular-aging research bundle: NAD+ + Epithalon + MOTS-c + SS-31 in a curated multi-mechanism design covering pineal/telomerase signaling (Epithalon), mitochondrial-derived peptide signaling (MOTS-c), and inner-membrane cardiolipin protection (SS-31). The four compounds target the cellular-aging research conversation from four distinct mechanism angles.
• Reconstitution math: documented in the reconstitution calculator — NAD+ molecular weight (663.43 g/mol) is larger than most research peptides, so volume planning differs.
• Precursor pairings: some research designs combine direct NAD+ with NMN or NR to probe pathway-entry kinetics; the choice is experiment-dependent.

Closing

NAD+ sits at the centre of cellular metabolism as a redox coenzyme and at the centre of cellular-aging research as the consumed substrate of the sirtuin, PARP and CD38 enzyme classes. Tissue NAD+ falls substantially with age in research-animal models, driven dominantly by rising CD38 activity, and the longevity-research literature documents that boosting NAD+ availability — directly or via precursors — reverses several aging-associated phenotypes in published research designs.

This guide documents what published peer-reviewed research has investigated. It is mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source NAD+ for laboratory research:

• NAD+ product page — full identifiers, 100 mg lyophilized vial, per-batch COA
• Longevity Stack — curated NAD+ + Epithalon + MOTS-c + SS-31 bundle for cellular-aging research designs
• Longevity research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.